Drug intelligence / Profile preview

Chufeng Yisun Decoction

Development stage: Unknown
Lead developer: Eye Hospital of China Academy of Chinese Medical Sciences
Administration: Oral

Overview

Chufeng Yisun Decoction is a traditional Chinese medicine (TCM) herbal formulation developed and studied by the Eye Hospital of China Academy of Chinese Medical Sciences. It is primarily indicated for the treatment and prevention of macular edema in patients who have undergone vitrectomy with silicone oil tamponade for proliferative diabetic retinopathy (PDR). The decoction is intended to reduce central macular thickness and improve visual acuity by addressing the underlying pathological changes associated with diabetic eye disease and post-surgical inflammation. As a multi-herb decoction, its mechanism likely involves anti-inflammatory and microcirculation-improving properties.

Other names: Chufeng Yisun Tang

Beyond the preview

Go deeper on Chufeng Yisun Decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chufeng Yisun Decoction.

Explore the full profile